251 related articles for article (PubMed ID: 12750359)
1. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.
Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
Int Immunol; 2003 Jun; 15(6):751-63. PubMed ID: 12750359
[TBL] [Abstract][Full Text] [Related]
2. [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66].
Jin S; Wang Y; Wang SJ; Zhang HZ; Li MX; Chen Y; Ge HL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):233-6, 242. PubMed ID: 15766414
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.
Peoples GE; Anderson BW; Fisk B; Kudelka AP; Wharton JT; Ioannides CG
Ann Surg Oncol; 1998 Dec; 5(8):743-50. PubMed ID: 9869522
[TBL] [Abstract][Full Text] [Related]
4. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Fisk B; Blevins TL; Wharton JT; Ioannides CG
J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
[TBL] [Abstract][Full Text] [Related]
5. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
6. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
7. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
8. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
9. Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient.
Verdegaal EM; Huinink DB; Hoogstraten C; Marijnissen AK; Gorsira MB; Claas FH; Osanto S
Hum Immunol; 1999 Dec; 60(12):1195-206. PubMed ID: 10626733
[TBL] [Abstract][Full Text] [Related]
10. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
[TBL] [Abstract][Full Text] [Related]
12. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma.
Bernhard H; Maeurer MJ; Jäger E; Wölfel T; Schneider J; Karbach J; Seliger B; Huber C; Storkus WS; Lotze MT; Meyer zum Büschenfelde KH; Knuth A
Scand J Immunol; 1996 Sep; 44(3):285-92. PubMed ID: 8795723
[TBL] [Abstract][Full Text] [Related]
13. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.
Würtzen PA; Claesson MH
Int J Cancer; 2002 Jun; 99(4):568-72. PubMed ID: 11992547
[TBL] [Abstract][Full Text] [Related]
14. Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.
Fisk B; Anderson BW; Gravitt KR; O'Brian CA; Kudelka AP; Murray JL; Wharton JT; Ioannides CG
Cancer Res; 1997 Jan; 57(1):87-93. PubMed ID: 8988046
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
16. Identification of melanoma-specific peptide epitopes by HLA-A2.1-restricted cytotoxic T lymphocytes.
Ge HL; Wang Y; Wang SJ; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2006 Feb; 38(2):110-8. PubMed ID: 16474902
[TBL] [Abstract][Full Text] [Related]
17. Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line.
Würtzen PA; Pedersen LO; Poulsen HS; Claesson MH
Int J Cancer; 2001 Sep; 93(6):855-61. PubMed ID: 11519048
[TBL] [Abstract][Full Text] [Related]
18. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
[TBL] [Abstract][Full Text] [Related]
19. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
20. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
